اعتلال الكلى السكري في داء السكري من النوع 2 وأمراض الكلى المزمنة: ماذا تفعل عندما لا يحقق علاج مثبط SGLT2 السيطرة على السكر في الدم

References

DOI: 10.1016/j.nefro.2024.11.002

• Patients with T2D and CKD with an eGFR ≥20 ml/min/1.73 m² should be treated with a sodium-glucose cotransporter-2 inhibitor and continue until end-stage kidney disease (dialysis or kidney transplant).
• Glucagon-like peptide-1 receptor agonists are recommended as additional pharmacological treatment, as they have proven cardiovascular benefit and, recently, kidney benefit in terms of CKD progression in people with T2D.
• Patients with T2D, an eGFR ≥ 25 ml/min/1.73 m², and increased albuminuria (uACR > 100 mg/g) on a stable maximal tolerated dose of RAS inhibitors should be treated with a GLP1RA with proven kidney benefit.